In 2024, Rohto Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Rohto Pharmaceutical has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021-2019 |
|---|---|---|---|---|
Total Scope 1 | 6,900a | 7,613a | 7,388a | |
Total Scope 2 | ||||
Market-Based | 3,322a | 5,109a | 5,936a | |
Location-Based | N/A | N/A | N/A | |
Total Scope 3 | 229,563a | 227,516b | 193,616b | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 3.8581a | 4.2489a | 4.5154a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Rohto Pharmaceutical amounted to 10,222 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Rohto Pharmaceutical decreased by 19.65%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Rohto Pharmaceutical were 6,900 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Rohto Pharmaceutical's Scope 1 emissions have increased by 45.6%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Rohto Pharmaceutical's Scope 1 emissions decreased by 9.37%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Rohto Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 3,322 tCO₂e using the market-based method.a
Since 2019, Rohto Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have decreased by 63.96%, reflecting a declining long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2023), Rohto Pharmaceutical's Scope 2 emissions (Market-Based) fell by 34.98% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2024, Rohto Pharmaceutical reported its Scope 2 emissions using the market-based method.a
In 2024, Rohto Pharmaceutical reported 229,563 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Rohto Pharmaceutical includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Rohto Pharmaceutical reported total Scope 3 emissions of 229,563 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 97.47% of these emissions originated from upstream activities such as purchased goods and capital goods, while 2.53% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), Rohto Pharmaceutical's Scope 3 emissions remained relatively stable, indicating that Rohto Pharmaceutical's emissions have plateaued with no significant change in its value chain footprint.ab
In 2024, Rohto Pharmaceutical reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Rohto Pharmaceutical's Scope 3 emissions were:a
In 2024, Rohto Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 6,900 tCO₂e and total revenues of USD 1,788 millions. This translates into an emissions intensity of 3.86 tCO₂e per millions USD.a
In 2024, Rohto Pharmaceutical reported a Scope 1 emissions intensity of 3.86 tCO₂e per millions USD. Compared to the peer group median of 4.78, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2024, Rohto Pharmaceutical ranked 11 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Rohto Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2024, Rohto Pharmaceutical reported a total carbon footprint of 239,785 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 0.19% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.ab
The largest contributor to Rohto Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 95.74% of the company's total carbon footprint, followed by Scope 1 emissions at 2.88%.a